SIC Score (Sepsis-Induced Coagulopathy)
Identifies sepsis-induced coagulopathy (SIC) as an early phase of DIC. Identifies patients who may benefit from anticoagulation.
Score interpretation
SIC score < 4, or PT + platelet points ≤ 2 (Iba 2017).
→ Monitor; recheck coagulation if the patient deteriorates.
SIC score ≥ 4 with PT + platelet points > 2; 28-day mortality 38 % in the derivation cohort — at risk of progressing to overt DIC.
→ Treat the underlying sepsis; consider anticoagulation per local protocol (ISTH 2019 guidance); repeat the ISTH DIC score.
Interpretation bands for the SIC Score. Apply clinical judgement and local guidance.
References
- Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):e017046.
- Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-1994.
Related
Curated clinical cross-links plus same-class fallbacks.
- Bivalirudin (PCI Anticoagulation) · Direct Thrombin Inhibitor / PCI
- Prothrombin Complex Concentrate (PCC) · Coagulation Factor Concentrate — Warfarin Reversal
- Bivalirudin · Anticoagulation
- Phytomenadione (Vitamin K1) · Vitamin K (Coagulation Factor Synthesis)
- Factor IX Concentrate · Coagulation Factor Replacement — Haemophilia B
- Fibrinogen Concentrate · Coagulation Factor Replacement — Hypofibrinogenaemia
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.